Abstract |
To evaluate ocular surface changes after withdrawal of Benzalkonium chloride (BAK) in patients with glaucoma in monotherapy with BAK-preserved prostaglandin. This was a prospective observational study. All patients underwent complete ophthalmologic examination and evaluation of ocular surface. A questionnaire was filled regarding symptoms of dry eye (Ocular Surface Disease Index [OSDI]) at the beginning of study. The treatment was switched to preservative-free tafluprost for 6 weeks and after this period, all patients were re-evaluated. All patients reported improvement of symptoms. The green lissamine test showed a significant improvement of the ocular surface, with most patients classified as light dry eye (P < 0.001). A significant improvement in the score (P < 0.001) was also found, with an average of 17.95 ± 5.35 points, which classifies the patients' symptoms in the normal to light zone. Benzalkonium chloride withdrawal reduced the signs and symptoms of dry eye in patients with primary open angle glaucoma (POAG).
|
Authors | Nara Lidia Vieira Lopes, Carolina P B Gracitelli, Maria Regina Chalita, Nubia Vanessa Lima de Faria |
Journal | Medical hypothesis, discovery & innovation ophthalmology journal
(Med Hypothesis Discov Innov Ophthalmol)
Vol. 8
Issue 1
Pg. 52-56
( 2019)
ISSN: 2322-4436 [Print] United States |
PMID | 30923724
(Publication Type: Journal Article)
|